Pharmaceutical and diagnostics giant Roche announced it will fund a $550 million diagnostic center in Indianapolis by 2030.
The manufacturing hub will produce Roche’s continuous glucose monitoring (CGM) systems for diabetes management.
The center will include research and development, laboratories, manufacturing, distribution, IT and administrative tasks.
According to the company, the new facility will create hundreds of jobs and expand production capabilities.
Roche produces almost 5.2 million Accu-Check diabetes test strips per year.
“The challenges of diabetes are pervasive, with millions of Americans living with the constant vigilance and countless daily decisions the disease requires,” Brad Moore, president and CEO of Roche Diagnostics North America, said in a statement.
“By expanding our manufacturing capabilities in Indianapolis, we ensure reliable access to innovative monitoring solutions for individuals living with diabetes in the U.S. and worldwide.”
THE LARGER TREND
In 2024, Respiree combined its vital sign monitoring device with Roche’s blood glucose device as a joint bedside offering. The tool uses machine learning models that predict clinical deterioration based on historical data and provide risk scores.
The device allows users to register patients with Respiree’s connected devices, monitor historical data and potential deterioration, and measure vital signs and blood sugar.
That same year, Roche integrated a suite of AI algorithms into its enterprise digital pathology software by collaborating with South Korean firm Deep Bio to power the navify digital pathology platform with prostate cancer analysis AI solution DeepDx Prostate.
The AI technology provides pathologists with gland-level Gleason grading, measurements of tissue and tumor and diagnosis support.
Glytec and Roche teamed up to allow the use of Glytec’s software and Roche’s point-of-care smart-device hospital blood glucose system, Cobas Pulse, in the U.S. and global markets.
According to Roche, Cobas Pulse’s strip architecture provides lab-like results and minimizes the need for repeat tests. The system will be used on all patient populations, including neonates and intensive care patients.
Other companies in the pharmaceutical space include Eli Lilly and Company. Earlier this month, Lilly and Purdue University expanded their alliance when Lilly announced an investment of up to $250 million over the next eight years.
The Lilly-Purdue 360 Initiative aims to achieve several key goals, such as discovering and accelerating the delivery of medicines to patients; bridging the gap between laboratory discoveries and clinical applications; creating more resilient, efficient and sustainable supply chains; and deploying innovative, scalable approaches to workforce development.
